Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

U50,488: a kappa-selective agent with poor affinity for mu1 opiate binding sites.

J A Clark1, G W Pasternak

  • 1Cotzias Laboratory of Neuro-Oncology Memorial Sloan-Kettering Cancer Center.

Neuropharmacology
|March 1, 1988
PubMed
Summary

U50,488 is a highly selective kappa opioid receptor ligand. Unlike other kappa agents, it shows minimal binding to mu1, mu2, and delta receptors, making it a valuable research tool.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Black Hole Spectroscopy and Tests of General Relativity with GW250114.

Physical review letters·2026
Same author

GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

Physical review letters·2025
Same author

First Study of the ^{139}Ba(n,γ)^{140}Ba Reaction to Constrain the Conditions for the Astrophysical i Process.

Physical review letters·2024
Same author

Improved Tensor Current Limit from ^{8}B β Decay Including New Recoil-Order Calculations.

Physical review letters·2024
Same author

Direct Mass Measurements to Inform the Behavior of ^{128m}Sb in Nucleosynthetic Environments.

Physical review letters·2024
Same author

Angular Correlations in the β Decay of ^{8}B: First Tensor-Current Limits from a Mirror-Nucleus Pair.

Physical review letters·2023

Area of Science:

  • Pharmacology
  • Neuroscience
  • Receptor Binding Assays

Background:

  • Potent kappa opioid receptor ligands often exhibit high affinity for mu receptors.
  • Previous studies confirmed U50,488's selectivity for kappa sites over mu2 and delta receptors.
  • The interaction of U50,488 with the mu1 receptor subtype was not well-characterized.

Purpose of the Study:

  • To investigate the selectivity profile of U50,488 across different opioid receptor subtypes, particularly mu1.
  • To determine if U50,488 represents a truly kappa-selective ligand.
  • To compare U50,488's binding characteristics with other known kappa-active agents.

Main Methods:

  • Radioligand binding assays were employed.
  • The affinity (Ki values) of U50,488 was measured for kappa, mu1, mu2, and delta opioid receptors.

Related Experiment Videos

  • Comparative binding affinities of other kappa agents to mu1 receptors were reviewed.

    • Main Results:

    • U50,488 demonstrated high selectivity for kappa sites (Ki 12 nM) compared to mu2 and delta receptors (Ki > 500 nM).
    • In contrast to other kappa agents (Ki < 1 nM), U50,488 exhibited poor affinity for mu1 receptors (Ki 370 nM).
    • These findings establish U50,488 as a highly kappa-selective compound with minimal interaction with mu and delta receptors.

    Conclusions:

    • U50,488 is a highly selective kappa opioid receptor agonist.
    • Its negligible binding to mu1, mu2, and delta receptors distinguishes it from other kappa ligands.
    • U50,488 serves as a valuable pharmacological tool for studying kappa receptor function.